Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018039652) SYSTEMS AND METHODS FOR DETERMINING AN ABNORMAL GLYCEMIC EVENT USING SURROGATES FOR GLUCOSE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

We claim:

1. A medical system comprising:

a medical device associated with a subject, wherein the medical device is

configured to sense a signal corresponding to a presence of a compound in at least one of: an exhalation breath, interstitial fluid, blood and urine, wherein the compound is a surrogate for glucose; and

a processor communicatively coupled to the medical device, the processor

configured to:

receive the signal corresponding to the presence of the compound;

determine the presence of the compound based on the received signal; and

determine the subject is experiencing an abnormal glycemic event in

response to the determined presence of the compound.

2. The medical system of claim 1 ,

wherein the medical device is an implantable medical device and comprises an indicator tag, wherein the indicator tag is responsive to the compound; and

wherein to sense a signal corresponding to the presence of the compound, the medical device is configured to sense light emanated from the indicator tag, wherein the light emanated from the indicator tag is in response to the indicator tag being exposed to light.

3. The medical system of claim 2, wherein to sense light emanated from the indicator tag, the medical device is configured to sense a fluorescence of the light emanated by the indicator tag.

4. The medical system of any of claims 2 and 3, wherein to sense light emanated from the indicator tag, the medical device is configured to sense a fluorescence lifetime effect of the indicator tag.

5. The medical system of any of claims 2-4, wherein the processor is configured to determine the presence of the compound based on the received signal by determining at least one of: a ratio of an intensity of the emanated light to an intensity of the exposed light and a ratio of a wavelength of the emanated light to a wavelength of the exposed light.

6. The medical system of any of claims 2-5,

wherein the exposed light comprises a first wavelength and a second wavelength and the emanated light comprises the first wavelength and the second wavelength; and

wherein the processor is configured to determine the presence of the compound based on the received signal by determining: a first absorption of the first wavelength by the indicator tag, a second absorption of the second wavelength by the indicator tag and comparing the first absorption to the second absorption.

7. The medical system of any of claims 2-6, wherein the processor is configured to determine a concentration of the compound based on the received signal.

8. The medical system of any of claims 2-7, wherein the indicator tag comprises at least one of: a glucose-responsive fluorescent hydrogel and AcetonaPhthone phenyl ethyl Propionate Hydroxyl Tungstate.

9. The medical system of any of claims 1 -8, wherein the compound is at least one of: hexane, ketones, catecholamine, Cortisol, epinephrine and/or nor-epinephrine.

10. The medical system of any of claims 1 -9, wherein the medical device is further configured to sense at least one of: the subject's acceleration, the subject's heart rate variability, a QT interval of the subject, a nerve transit time of the subject, the subject's reflex sensitivity, an autonomic tone of the subject and the subject's feedback to a cognitive test.

1 1. A method comprising:

sensing, using a medical device associated with a subject, a physiological

parameter including at least one of: an acceleration, heart rate variability, a QT interval, a nerve transit time, reflex sensitivity, an autonomic and feedback to a cognitive test;

correlating the sensed parameter to a blood glucose level; and

determining, for the subject, using a processing device, an abnormal glycemic event based on the correlation of the sensed parameter to the blood glucose level.

12. The method of claim 1 1 , further comprising sensing a signal corresponding to a presence of a compound in at least one: an exhalation breath, interstitial fluid, blood and urine, wherein the compound is a surrogate for glucose.

13. The method of claim 12, wherein the medical device is an implantable medical device and comprises an indicator tag exposed to interstitial fluid of the subject, wherein the indicator tag is responsive to the presence of the compound in interstitial fluid;

wherein sensing a signal corresponding to a presence of a compound comprises exposing the indicator tag to light and receiving emanated light from the indicator tag in response to the indicator tag being exposed to light.

14. The method of any of claims 12-13, wherein the indicator tag comprises at least one of: a glucose-responsive fluorescent hydrogel and AcetonaPhthone phenyl ethyl Propionate Hydroxyl Tungstate.

15. The method of any of claims 12-14, wherein the compound is at least one of: hexane, ketones, catecholamine, Cortisol, epinephrine and/or nor-epinephrine.